Stock Events

Biotest 

$34.7
2
+$0.1+0.29% Friday 12:05

Statistics

Day High
41.45
Day Low
41.45
52W High
48.69
52W Low
22.31
Volume
2,176
Avg. Volume
-
Mkt Cap
1.79B
P/E Ratio
0
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
May 22
$0.04
May 21
$0.05
May 20
$0.04
May 19
$0.04
May 18
$0.05

Earnings

4MayConfirmed
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q1 2022
-0.46
-0.3
-0.15
0
Expected EPS
N/A
Actual EPS
-0.1389

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIESF. It's not an investment recommendation.

About

Pharmaceuticals: Other
Health Technology
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; Anti-SARS-CoV-2 hyperimmunoglobulin for COVID-19 treatment; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Tiancheng (Germany) Pharmaceutical Holdings AG.
Show more...
CEO
Dr. Michael Ramroth
Employees
1963
Country
DE
ISIN
DE0005227235
WKN
000522723

Listings